Incidence and Associated Factors of Neutralizing Anti-Interferon Antibodies among Chronic Hepatitis C Patients Treated with Interferon in Taiwan

References

• Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501–6.
   Google Scholar
• Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506–10.
   Google Scholar
• Vallbracht A, Treuner J, Flehmig B, Joester KE, Niethammer D. Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981;289(5797):496–7.
   Google Scholar
• Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991;163:882–5.
   PubMed Web of Science ®Google Scholar
• Arai K, Shindo M, Okuno T. Anti-interferon antibody in chronic hepatitis C. Nippon Rinsho 1994;52:1929–34.
   PubMedGoogle Scholar
• Bonetti P, Diodati G, Drago C, Casarin C, Scaccabarozzi S, Realdi G, et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon alpha-2 alpha [see comments]. J Hepatol 1994;20(3):416–20.
   PubMed Web of Science ®Google Scholar
• Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer 1986; 57(8 Suppl):1709–15.
   PubMed Web of Science ®Google Scholar
• Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, et al. Neutralizing antibodies to recombinant alphainterferon and response to therapy in chronic hepatitis C virus infection. Liver 1993;13:146–50.
   PubMedGoogle Scholar
• Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 1989;8:351–7.
   Google Scholar
• Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy. Clin Exp Immunol 1996;104:384–7.
   PubMed Web of Science ®Google Scholar
• Roffi L, Mels GC, Antonelli G, Bellati G, Panizzuti F, Piperno A, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatology 1995;21: 645–9.
   PubMed Web of Science ®Google Scholar
• Bonino F, Baldi M, Negro F, Oliveri F, Colombatto P, Bellati G, et al. Clinical relevance of anti-interferon antibodies in the serum of chronic hepatitis C patients treated with interferonalpha. J Interferon Cytokine Res 1997;17 Suppl 1:S35–8.
   PubMed Web of Science ®Google Scholar
• Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, et al. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C. Clin Exp Immunol 1994;97:4–9.
   Google Scholar
• Steis RG, Smith JW 2nd, Urba WJ, Clark JW, Itri LM, Evans LM, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988;318: 1409–13.
   Google Scholar
• Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 1989;9 Suppl 1:S51–60.
   Google Scholar
• Clifford BD, Donahue D, Smith L, Cable E, Luttig B, Manns M, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995;21:613–9.
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293–9.
   PubMed Web of Science ®Google Scholar
• Sheu JC, Wang JT, Wang TH, Wang CY, Yang PM, Huang GT, et al. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993;17:192–8.
   Google Scholar
• Mosnier JF. Current anatomico-pathological classification of hepatitis: characteristics of HCV infection. Nephrol Dial Transplant 1996;11 Suppl 4:12–5.
   PubMed Web of Science ®Google Scholar
• Yu ML, Chuang WL, Chen SC, Lu SN, Wang JH, Lin ZY, et al. Treatment of chronic hepatitis C with interferon-alpha: a preliminary report. Kaohsiung J Med Sci 1996;12:581–9.
   PubMedGoogle Scholar
• Okamoto H, Tokita H, Sakamoto M, Horikita M, Kojima M, Iizuka H, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74(Pt 11):2385–90.
   PubMed Web of Science ®Google Scholar
• Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med 1986; 80:223–8.
   PubMed Web of Science ®Google Scholar
• Weck PK, Leventhal BG, Brand C, Finter NB. Detection and incidence of neutralizing antibodies to interferon-alpha-n1. J Interferon Res 1989;9 Suppl 1:S37–43.
   PubMedGoogle Scholar
• Allen G, Fantes KH. A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature 1980; 287(5781):408–11.
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, et al. Virologic factors related to interferon-alpha induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol 2000;142:431–7.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473–81.
   PubMed Web of Science ®Google Scholar
• Beld M, Penning M, Lukashov V, McMorrow M, Roos M, Pakker N, et al. Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters. Virology 1998;244:504–12.
   PubMed Web of Science ®Google Scholar
• Toyoda H, Nakano S, Kumada T, Takeda I, Sugiyama K, Osada T, et al. Comparison of serum hepatitis C virus RNA concentration by branched DNA probe assay with competitive reverse transcription polymerase chain reaction as a predictor of response to interferon-alpha therapy in chronic hepatitis C patients. J Med Virol 1996;48:354–9.
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995;21:291–7.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Tokyo-Chiba Hepatitis Research Group. Gastroenterology 1997;113:558–66.
   Google Scholar
• Yu ML, Chuang WL, Lu SN, Chen SC, Wang JH, Lin ZY, et al. The genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection in southern Taiwan. Kaohsiung J Med Sci 1996;12:605–12.
   PubMedGoogle Scholar